Table 3.
Summary of adverse events among the included RCTs
| CGRP mAb(n/N) | Placebo(n/N) | I2 | odds ratio [95% CI] | p value | |
|---|---|---|---|---|---|
| Withdrawal due to AEs | 38/1898 | 35/2504 | 0% | 1.46[0.90,2.37] | 0.12 |
| Specific AEs | |||||
| any serious events | 1115/1898 | 1472/2504 | 25% | 1.02[0.90,1.15] | 0.79 |
| dizziness | 29/835 | 31/1313 | 0% | 1.47[0.87,2.49] | 0.15 |
| fatigue | 36/1515 | 39/1825 | 0% | 1.15[0.72,1.83] | 0.55 |
| influenza | 26/1231 | 41/1758 | 5% | 0.87[0.53,1.45] | 0.6 |
| injection site pain | 167/1501 | 148/1837 | 35% | 1.44[1.13,1.84] | 0.004 |
| migraine | 12/1086 | 17/1379 | 11% | 0.83[0.41,1.71] | 0.62 |
| nasopharyngitis | 115/1817 | 163/2422 | 1% | 0.96[0.75,1.24] | 0.78 |
| nausea | 34/1553 | 61/1919 | 0% | 0.68[0.45,1.05] | 0.08 |
| upper respiratory tract infection | 117/1692 | 123/2072 | 0% | 1.25[0.96,1.63] | 0.1 |
| urinary tract infection | 22/1270 | 33/1519 | 0% | 0.91[0.53,1.56] | 0.73 |